| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.29.5865 |
| P698 | PubMed publication ID | 21172893 |
| P50 | author | Hope Rugo | Q55975497 |
| Joyce O'Shaughnessy | Q88307619 | ||
| P2093 | author name string | Howard A Burris | |
| Maoxia Zheng | |||
| Svetislava J Vukelja | |||
| Ian E Krop | |||
| Yu-Waye Chu | |||
| Charles L Vogel | |||
| Lukas Amler | |||
| Sandhya Girish | |||
| Steven Limentani | |||
| Elizabeth Tan-Chiu | |||
| Barbara Klencke | |||
| Rachel A Borson | |||
| Richard A Michaelson | |||
| P2860 | cites work | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| breast cancer | Q128581 | ||
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| P304 | page(s) | 398-405 | |
| P577 | publication date | 2010-12-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | |
| P478 | volume | 29 |
| Q42906644 | 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. |
| Q33442957 | A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates |
| Q57911965 | A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy |
| Q46349887 | A cancer trial scandal and its regulatory backlash |
| Q37571113 | A general approach to site-specific antibody drug conjugates |
| Q28487973 | A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma |
| Q28544636 | A mechanistic tumor penetration model to guide antibody drug conjugate design |
| Q33430299 | A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer |
| Q54507904 | A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. |
| Q40835274 | A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma |
| Q33402778 | A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer |
| Q41344028 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience |
| Q38644521 | A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. |
| Q36740744 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments |
| Q33886306 | Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer. |
| Q34389275 | Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential |
| Q33414335 | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer |
| Q37378269 | Ado-trastuzumab emtansine and radium 223 dichloride |
| Q33415915 | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series |
| Q38235934 | Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate |
| Q37601692 | Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. |
| Q35989963 | Advances in first-line treatment for patients with HER-2+ metastatic breast cancer |
| Q49885166 | Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients |
| Q57452661 | Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing |
| Q43175985 | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. |
| Q44026744 | Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer |
| Q57291727 | An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC |
| Q54439772 | An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. |
| Q36938365 | Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel |
| Q47750583 | Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer |
| Q90171453 | Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer |
| Q35889630 | Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties |
| Q39210427 | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review |
| Q47568807 | Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future |
| Q53739135 | Antibody-Drug Conjugates for Cancer Therapy. |
| Q46209550 | Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. |
| Q26800175 | Antibody-drug conjugates as novel anti-cancer chemotherapeutics |
| Q38864720 | Antibody-drug conjugates for cancer therapy. |
| Q38334139 | Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. |
| Q38239854 | Antibody-drug conjugates: an emerging modality for the treatment of cancer |
| Q38665425 | Antibody-mediated delivery of therapeutics for cancer therapy. |
| Q38856969 | Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). |
| Q46866013 | Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. |
| Q47743713 | Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q35653820 | Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer |
| Q43751494 | Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics |
| Q38408138 | Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand. |
| Q35068522 | Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. |
| Q51108833 | Breast Cancer Immunotherapy. |
| Q38215394 | Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. |
| Q37833497 | Breast cancer in 2010: Novel targets and therapies for a personalized approach |
| Q38072263 | Breast cancer in 2012: New drugs, new knowledge, new targets |
| Q39428826 | Breast cancer treatment-induced cardiotoxicity |
| Q37098302 | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity |
| Q54586053 | Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents? |
| Q38791220 | Cardiac Complications of HER2-Targeted Therapies in Breast Cancer |
| Q38852051 | Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment |
| Q90212189 | Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy |
| Q26774513 | Changing strategies for target therapy in gastric cancer |
| Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
| Q36653094 | Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer |
| Q24632855 | Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer |
| Q27005742 | Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy |
| Q39564060 | Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models |
| Q37995939 | Combining immunotherapy and targeted therapies in cancer treatment |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q37733237 | Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer |
| Q37946797 | Current and emerging targeted therapies for metastatic breast cancer |
| Q37330128 | Current approaches and future directions in the treatment of HER2-positive breast cancer |
| Q35584741 | Current targeted therapies in breast cancer: clinical applications in the elderly woman |
| Q38137253 | Design and evaluation of radiolabeled tracers for tumor imaging |
| Q38017203 | Designing immunoconjugates for cancer therapy |
| Q38624597 | Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. |
| Q34114794 | Discovery of internalizing antibodies to tumor antigens from phage libraries |
| Q33421995 | Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction |
| Q38084826 | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. |
| Q38061647 | Drug-conjugated antibodies for the treatment of cancer |
| Q37940203 | Dual HER2-targeted approaches in HER2-positive breast cancer |
| Q34169075 | Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review |
| Q39816545 | Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer |
| Q47136161 | Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial |
| Q38119307 | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab |
| Q92768203 | Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy |
| Q46873437 | EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer |
| Q60950660 | EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma |
| Q38073792 | Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. |
| Q33433942 | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer |
| Q38920359 | Evolving Strategies for Target Selection for Antibody-Drug Conjugates |
| Q90212184 | Factors Affecting the Pharmacology of Antibody-Drug Conjugates |
| Q37066113 | Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. |
| Q42337744 | Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany |
| Q49056513 | From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer |
| Q34619403 | GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer |
| Q41694155 | Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. |
| Q35576706 | HER2 expression and efficacy of T-DM1 |
| Q53691004 | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
| Q33358380 | HER2-positive breast cancer: a new piece of the puzzle |
| Q30524836 | High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production |
| Q27025863 | Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer |
| Q42732010 | IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA. |
| Q38042256 | Immunoconjugates and long circulating systems: origins, current state of the art and future directions |
| Q38787696 | Immunotherapy for breast cancer: past, present, and future |
| Q57134389 | Immunotherapy of breast cancer |
| Q37998453 | Improving treatment of HER2-positive cancers: opportunities and challenges |
| Q38557525 | In vivo biotransformations of antibody-drug conjugates |
| Q26771931 | Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1 |
| Q36088788 | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications |
| Q92457343 | Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report |
| Q57495756 | Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer |
| Q37029370 | Linked-in: design and efficacy of antibody drug conjugates in oncology |
| Q37698957 | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models |
| Q37859389 | Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer |
| Q38233292 | Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches? |
| Q38255064 | Mechanism-based cancer therapy: resistance to therapy, therapy for resistance |
| Q35624814 | Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance |
| Q38204975 | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. |
| Q38960075 | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates |
| Q90048092 | Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes |
| Q56624496 | Metastasiertes Mammakarzinom |
| Q38186568 | MicroRNAs: master regulators of drug resistance, stemness, and metastasis. |
| Q37631514 | Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? |
| Q38071374 | Monoclonal antibodies in oncology therapeutics: present and future indications |
| Q94475380 | Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer |
| Q35111429 | Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells |
| Q92953592 | Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo |
| Q37016382 | New developments in the treatment of HER2-positive breast cancer |
| Q37144315 | New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available |
| Q33579636 | Next generation of antibody therapy for cancer |
| Q26747729 | Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine |
| Q57106864 | Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs |
| Q36366709 | Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials |
| Q39112394 | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach |
| Q38152742 | Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations |
| Q48131836 | Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis |
| Q37580443 | Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study |
| Q30544833 | Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. |
| Q36408570 | Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer |
| Q38017732 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. |
| Q45006316 | PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine |
| Q36653978 | Particle shape enhances specificity of antibody-displaying nanoparticles |
| Q37241496 | Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q27851691 | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer |
| Q38022192 | Pharmacokinetic considerations for antibody drug conjugates |
| Q90211749 | Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients |
| Q44895959 | Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. |
| Q33418305 | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer |
| Q36934332 | Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma |
| Q36582681 | Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines |
| Q38220276 | Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. |
| Q33954595 | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
| Q37671599 | Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. |
| Q38271031 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer |
| Q38131563 | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates |
| Q27015048 | Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine |
| Q35343184 | Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival |
| Q64991628 | Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules? |
| Q34308692 | Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers |
| Q37248289 | RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation |
| Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
| Q28083123 | Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates |
| Q37950515 | Recent developments in treatment stratification for metastatic breast cancer |
| Q34500802 | Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer |
| Q41037554 | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer |
| Q92413714 | Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer |
| Q39591068 | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q35747298 | Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer |
| Q27003258 | Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer |
| Q33441316 | Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer |
| Q33430735 | Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis |
| Q37100575 | Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q44829143 | Site-specific chemical modification of antibody fragments using traceless cleavable linkers |
| Q57911963 | Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature |
| Q36256669 | Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer |
| Q30590270 | Strategies for modern biomarker and drug development in oncology |
| Q38103883 | Strategies to address drug interaction potential for antibody-drug conjugates in clinical development |
| Q34028831 | Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles |
| Q39685521 | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab |
| Q35268982 | TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation |
| Q35612933 | Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial |
| Q47559665 | Targeted Therapies Against Growth Factor Signaling in Breast Cancer |
| Q35687574 | Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. |
| Q38058816 | Targeted drug delivery for cancer therapy: the other side of antibodies |
| Q35372584 | Targeted therapies for breast cancer |
| Q36245324 | Targeted therapies in breast cancer: are heart and vessels also being targeted? |
| Q38007119 | Targeted therapy for gastric cancer. |
| Q35208654 | Targeting the HER/EGFR/ErbB family to prevent breast cancer. |
| Q37862077 | Targeting the human EGFR family in esophagogastric cancer |
| Q37974246 | Targeting the subtypes of breast cancer: rethinking investigational drugs |
| Q46431111 | The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment |
| Q36064912 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer |
| Q37992829 | The adjuvant treatment of HER2-positive breast cancer |
| Q36745332 | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. |
| Q38092648 | The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics |
| Q27021990 | The development of immunoconjugates for targeted cancer therapy |
| Q84560547 | The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma |
| Q38686601 | The future of antiviral immunotoxins |
| Q36097890 | The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma |
| Q33840201 | The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. |
| Q34412979 | The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? |
| Q36180078 | The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies |
| Q38018259 | The role of targeted therapy and biomarkers in breast cancer treatment |
| Q33409083 | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q50896680 | Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. |
| Q39068453 | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
| Q35875708 | Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q35034559 | Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience |
| Q38974785 | Trastuzumab cardiotoxicity: from clinical trials to experimental studies |
| Q27851917 | Trastuzumab emtansine for HER2-positive advanced breast cancer |
| Q38417241 | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer |
| Q38088038 | Trastuzumab emtansine in breast cancer |
| Q33415375 | Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients |
| Q27853001 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial |
| Q38198573 | Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy |
| Q47795804 | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer |
| Q38101890 | Trastuzumab emtansine: first global approval |
| Q33759627 | Trastuzumab emtansine: mechanisms of action and drug resistance |
| Q37387449 | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer |
| Q35891822 | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
| Q36585636 | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer |
| Q35869998 | Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report. |
| Q36220464 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer |
| Q34326536 | Treating breast cancer in the 21st century: emerging biological therapies |
| Q35740877 | Treatment of HER2-positive breast cancer. |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
| Q38162127 | Trends in cancer-targeted antibody-drug conjugates. |
| Q36252918 | Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers |
| Q38086872 | Tubulin: an example of targeted chemotherapy |
| Q38094627 | Tumour vasculature targeting agents in hybrid/conjugate drugs |
| Q28079391 | Twenty years of anti-HER2 therapy-associated cardiotoxicity |
| Q38014920 | Using antibodies to target cancer therapeutics |
| Q38262066 | Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates |
| Q42174238 | Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells |
| Q37576694 | When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease |
| Q28067696 | Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine? |
| Q39794283 | [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer |
Search more.